Editas Medicine, Inc. Profile Avatar - Palmy Investing

Editas Medicine, Inc.

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops …

Biotechnology
US, Cambridge [HQ]
Strategy & Leadership

Officers & BofD Beta

  • Form 3/4/5
  • Proxy DEF-14A

Total Compensation

- No data, only available if we have DEF 14A compensations in place -
Officers
Name & Position Research Last Appearance
- No data available -
Board of Directors (BofD)
Name & Position Research Last Appearance
- No data available -
End of EDIT's Analysis
CIK: 1650664 CUSIP: 28106W103 ISIN: US28106W1036 LEI: - UEI: -
Secondary Listings
EDIT has no secondary listings inside our databases.